- Home
- SPRY vs DYN Comparison
SPRY vs DYN Comparison
Compare SPRY & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- DYN
- Stock Information
- Founded
- SPRY 2015
- DYN 1984
- Country
- SPRY United States
- DYN United States
- Employees
- SPRY N/A
- DYN N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- DYN Medicinal Chemicals and Botanical Products
- Sector
- SPRY Health Care
- DYN Health Care
- Exchange
- SPRY Nasdaq
- DYN Nasdaq
- Market Cap
- SPRY 1.4B
- DYN 1.4B
- IPO Year
- SPRY N/A
- DYN 2020
- Fundamental
- Price
- SPRY $15.69
- DYN $10.32
- Analyst Decision
- SPRY Strong Buy
- DYN Strong Buy
- Analyst Count
- SPRY 4
- DYN 14
- Target Price
- SPRY $28.75
- DYN $44.57
- AVG Volume (30 Days)
- SPRY 1.2M
- DYN 2.5M
- Earning Date
- SPRY 08-05-2025
- DYN 08-11-2025
- Dividend Yield
- SPRY N/A
- DYN N/A
- EPS Growth
- SPRY N/A
- DYN N/A
- EPS
- SPRY N/A
- DYN N/A
- Revenue
- SPRY $97,122,000.00
- DYN N/A
- Revenue This Year
- SPRY N/A
- DYN N/A
- Revenue Next Year
- SPRY $140.40
- DYN N/A
- P/E Ratio
- SPRY N/A
- DYN N/A
- Revenue Growth
- SPRY 971120.00
- DYN N/A
- 52 Week Low
- SPRY $7.55
- DYN $6.36
- 52 Week High
- SPRY $18.51
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- SPRY 60.81
- DYN 34.25
- Support Level
- SPRY $14.77
- DYN $10.56
- Resistance Level
- SPRY $16.23
- DYN $15.23
- Average True Range (ATR)
- SPRY 0.73
- DYN 1.01
- MACD
- SPRY 0.12
- DYN -0.47
- Stochastic Oscillator
- SPRY 84.68
- DYN 4.10
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.